Maria Amélia Santos

Prof. Maria Amélia Santos

Centro de Química Estrutural and Departamento de Engenharia Química, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal
orcid

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Pharmacological Reports
Verified
Journal Article
Closed access
KCKaram Chand
Karam Chand
RARajeshwari
Rajeshwari
AHAsha Hiremathad
Asha Hiremathad
MSMahak Singh
Mahak Singh
MSMaria Amélia Santos
Maria Amélia Santos
DKDr.Rangappa Keri
Dr.Rangappa Keri

1 January 2012 in Coordination Chemistry Reviews
Verified
Journal Article
Closed access
MSMaria Amélia Santos
Maria Amélia Santos
Sérgio M. MarquesSérgio M. Marques
Sérgio M. Marques
SCSílvia Chaves
Sílvia Chaves

1 August 2013 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
RKRangappa S. Keri
Rangappa S. Keri
CQCatarina Quintanova
Catarina Quintanova
Sérgio M. MarquesSérgio M. Marques
Sérgio M. Marques
Raquel EstevesRaquel Esteves
Raquel Esteves
SCSandra Morais Cardoso
Sandra Morais Cardoso
MSMaria Amélia Santos
Maria Amélia Santos

1 January 2018 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
LPLuca Piemontese
Luca Piemontese
DTDaniel Tomás
Daniel Tomás
AHAsha Hiremathad
Asha Hiremathad
Vito CapriatiVito Capriati
Vito Capriati
ECEmanuel Candeias
Emanuel Candeias
MSMaria Amélia Santos
Maria Amélia Santos
A new series of multifunctional hybrids, based on the structure of the donepezil (DNP) drug, have been developed and evaluated as potential anti Alzheimer’s disease (AD) agents. The rationale of this study was the conjugation of a benzylpiperidine/benzylpiperazine moiety with derivatives of bioactive heterocyclics (benzimidazole or benzofuran), to mimic the main structure of DNP and to endow the hybrids with additional relevant properties such as inhibition of amyloid beta (Aβ) peptide aggregation, antioxidant activity and metal chelation. Overall, they showed good activity for AChE inhibition (IC50=4.0–30.0 μΜ) and moderate ability for inhibition of Aβ1–42 self-mediated aggregation. The hybrids containing chelating groups showed improvement in the inhibition of Cu-induced Aβ42 aggregation and the antioxidant capacity. Moreover, neuroprotective effects of these compounds were evidenced in neuroblastoma cells after Aβ1–42 induced toxicity. Structure–activity relationship allowed the identification of some promising compounds and the main determinant structural features for the targeted properties. Graphical Abstract

1 March 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AHAsha Hiremathad
Asha Hiremathad
RKRangappa S. Keri
Rangappa S. Keri
Raquel EstevesRaquel Esteves
Raquel Esteves
SCSandra Morais Cardoso
Sandra Morais Cardoso
SCSílvia Chaves
Sílvia Chaves
MSMaria Amélia Santos
Maria Amélia Santos

24 October 2016 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
MSMaria Amélia Santos
Maria Amélia Santos
KCKaram Chand
Karam Chand
SCSílvia Chaves
Sílvia Chaves
Alzheimer's disease (AD) is a serious progressive neurological disorder, characterized by impaired cognition and profound irreversible memory loss. The multifactorial nature of AD and the absence of a cure so far have stimulated medicinal chemists worldwide to follow multitarget drug-design strategies based on repositioning approved drugs. This review describes a summary of recently published works focused on tailoring new derivatives of US FDA-approved acetylcholinesterase inhibitors, in addition to huperzine (a drug approved in China), either by hybridization with other pharmacophore elements (to hit more AD targets), or by combination of two FDA-approved drugs. Besides the capacity for improving the cholinergic activity, these polyfunctional derivatives are also able to tackle other important neuroprotective properties, such as anti-β-amyloid aggregation, scavenging of radical oxygen species, modulation of redox-active metals or inhibition of monoamine oxidase, thereby resulting in potentially novel an...